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ABSTRACT 
Context: Diabetes mellitus (DM) contributes to a major chunk of morbidity, mortality, and 
healthcare cost on a global level. The prevalence of DM is rising alarmingly, worldwide and India. 
Comprehensive Diabetes Care (CDC) is a combination of Panchakarma and diet management.  
Aims: This study was conducted to evaluate the effect of CDC on Glycosylated hemoglobin 
(HbA1c), body mass index (BMI), body weight, abdominal girth and dependency on conventional 
therapy in DM Patients. 
Setting and Design: This observational study was conducted in July 2017, wherein the data of 
obese Type II DM patients (HbA1c >6.5%) who attended out-patient departments (OPDs) at 
Madhavbaug clinics in Maharashtra, India were identified.  
Materials and Methods: Data of patients who were administered CDC (60-75 minutes) with 
minimum 6 sittings over 90 days (± 15 days) were considered. Variables were compared between 
day 1 and day 90 of CDC. 
Results: Out of 27 patients, 22 were included for analysis, out of which 10 were males while 12 
females. CDC showed significant improvement in HbA1c 1.1% (from 8.80 ± 0.93 to 6.98 ± 1.73; 
p<0.001), BMI by 2.66 (from 33.79 ± 3.80 to 31.13 ± 3.91, p< 0.001), weight by 6.56 kg (from 83.67 
± 11.28 to 77.11 ± 12.27, p<0.001). Abdominal girth (from 104.34 ± 9.74 to 96.97 ± 11.93; 
p<0.001), also showed significant reduction. Dependency on concomitant medicines was reduced, 
with the number of patients on no concomitant medicines increasing from 27% to 41%. 
Conclusion: Comprehensive Diabetes Care Management Program found to be efficacious; by 
reducing HbA1c, as well as reducing dependency on allopathic medications. 
KEYWORDS: Comprehensive Diabetes Care, CDC, Panchakarma, Glycosylated HB, HbA1C, BMI, 
DM, Alternative Medicine. 
INTRODUCTION
Diabetes mellitus (DM) contributes to a major 
chunk of morbidity, mortality, and health care cost on 
a global level. The prevalence of DM is rising 
alarmingly, worldwide.[1] India is only 2nd to China, in 
terms of prevalence of DM, with a prevalence rate of 
around 10%, i.e. every 10th adult in India is suffering 
from DM.[2] According to WHO report, about 30 
people die per 1Lakh population in India, due to 
diabetic complications.[3] 
Conventionally DM is diagnosed based on 
blood glucose/sugar levels (BSL), fasting levels more 
than or equal to 126 mg/dl and post prandial levels 
more than or equal to 140 mg/dl is considered as a 
DM. In recent decade diagnosis is also done by 
measuring glycosylated hemoglobin (HbA1c), since it 
reflects blood sugar control over the past 2-3 months. 
HbA1c levels more than 6.5% is considered as DM, 
5.7% to 6.4% as a borderline case/ prediabetes, and 
less than 5.7% as normal. Target HbA1c for 
treatment strategies are taken as below 6.5%.[4] 
DM is dreaded due to its complications, which 
are short term and long term, macrovascular and 
microvascular. Macrovascular complications include 
myocardial infarction, coronary artery disease, 
stroke, cerebrovascular disease, peripheral vascular 
disease, etc. Microvascular complications include 
retinopathy, neuropathy, and nephropathy. Out of 
these, cardiovascular complications are leading cause 
of morbidity and mortality in diabetic patients.[5] 
Diabetic neuropathy may manifest as foot ulcers, 
sexual dysfunction in young males, amputation, 
etc.[6,7] Amongst microvascular complications, 
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nephropathy is leading cause of morbidity and 
mortality in diabetic patients.[8] The prevalence of 
retinopathy in diabetics is also increasing these 
days.[9] It has been postulated from findings of 
various epidemiological studies that certain cancers 
are more common in diabetics like, cancers of breast, 
kidney, colo-rectal, bladder, etc.[10,11] 
The current management plan includes 
lifestyle modification, including dietary modifications 
and physical exercise on a daily basis plus 
pharmacological management (oral antidiabetic 
drugs).  
Antidiabetic drugs/oral hypoglycemic agents 
(OHA) should be initiated only if a lifestyle 
modification fails to reduce HbA1c below 6.5% after 
2 months. Major class of OHAs includes Biguanides 
(Metformin), Thiazolidinediones (Pioglitazone), 
Sulphonylureas (Glimepiride), Dipeptidyl peptidase-4 
(DPP-4) inhibitors like Teneligpiltin, Sodium glucose 
cotransporter-2 inhibitors (canagliflozin). All these 
drugs act either, by reducing blood glucose via 
increasing tissue uptake, decreasing endogenous 
glucose production, preventing breakdown of 
incretins, etc. Guidelines suggest that, if baseline 
HbA1c is > 9% or it remains >7.5% despite 1 OHA, 
then combination of 2 OHAs should be given.[12] 
But, these drugs are associated with a wide 
variety of adverse effects like hypoglycemia (almost 
all classes), megaloblastic anemia (biguanides), 
pancreatitis, upper respiratory tract infections 
(gliptins), ketoacidosis, bone fractures (SGLT2 
inhibitors), lipodystrophy at injection site (insulin), C 
cell tumour of thyroid (GLP1 agonist), etc.[13] In a 
multicentric study on diabetic patients, it was found 
that adherence of patients to antidiabetic drugs was 
only 58%. The investigators of the study attributed 
this low adherence to cost of therapy, adverse effects 
of medications. Also, despite numerous guidelines for 
DM, its prevalence is rising continuously.[14] Thus, it is 
the need of the hour to explore alternate forms of 
antidiabetic therapy, which can ameliorate the 
factors associated with low adherence to allopathic 
antidiabetic drugs. 
The therapeutic benefit of allopathic 
antidiabetic drugs in diabetes is due to their blood 
glucose lowering action. Several studies have shown 
similar effects, with significant reduction in 
Glycosylated Hemoglobin (HbA1c), Fasting and Post 
Prandial Blood Glucose (FBG, PPBG) levels and lipids, 
by using herbal drugs, which serve as interesting 
potential targets for newer therapeutic options for 
treatment of DM.[15,16,17] 
Panchakarma is multi-step internal 
purification process. Panchkarma therapy in 
Ayurveda practice is administered in chronic phase 
of the disease, while herbal drugs are preferred in 
acute phase. Comprehensive Diabetes Care (CDC) 
combines Panchakarma and diet management. Under 
this management program, Panchakarma is 
advocated through three techniques-  
Snehana i.e. oleation, Swedana i.e. passive 
heat therapy and Basti i.e. per rectal drug 
administration. Panchakarma techniques are already 
well established in literature, as detoxifying 
procedures.[18,19] DM is found to be linked with 
depression, reduction in quality of life, etc.[20]Hence, 
we planned an Observational study to investigate the 
efficacy of the CDC, as add-on therapy to standard 
anti-diabetic therapy in patients with DM. We 
evaluated the effect of CDC on HbA1c, weight, body 
mass index (BMI), abdominal girth, and dependency 
of these diabetic patients on standard conventional 
oral antidiabetic medications. 
Since, numerous factors play a role in 
causation, progression of DM, its management should 
be multi-pronged. Given the fact that Ayurveda may 
serve as potent alternative therapy, its efficacy in DM 
should be tested.[15,17,21] Hence, we planned this 
observational study to investigate the effect of the 
CDC, as add on therapy to standard anti-diabetic 
therapy in obese patients with type II diabetes 
mellitus. We evaluated the effect of CDC on HbA1c, 
body mass index (BMI), body weight, dependency on 
oral hypoglycemic drugs/ agents, and abdominal 
girth. 
MATERIALS AND METHODS 
This was an Observational study conducted 
between July 2017, wherein we identified the data of 
obese patients suffering from type II DM (HbA1c ≥ 
6.5%, BMI ≥ 30) [4,5] of either gender and any age, and 
who had attended the out-patient departments 
(OPDs) at multiple Madhavbaug clinics located in 
various cities of Maharashtra, India. The data of 
patients who had been administered CDC with 
minimum 6 sittings over a span of 90 days (± 15 
days) were considered for the study, out of which 4 
sittings were done in the 1st month, and 1 sitting per 
month for next 2months. These patients were 
maintained on a diet plan of 800-1000 calories intake 
per day, according to patient medical records. The 
diet plan consisted of low carbohydrates, moderate 
proteins, and low fats. Cases were identified, and data 
were assessed from the records of Madhavbaug 
clinics in Maharashtra. The selection was based upon 
the availability of complete relevant baseline data 
(day 1 of CDC) and final day data (day 90 of CDC) of 
the patients. The information about prescribed 
concomitant medicines, if any, was also noted down.  
The CDC is a 3-step procedure which was 
performed on the patients of type II DM after a light 
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breakfast. One sitting of the procedure took 65-75 minutes, as described in table 1. [19, 22] 
Table 1: Study Treatment: Comprehensive Diabetes Care (CDC) 
Step of CDC Type of Therapy Herbs used for therapy Duration of Therapy 
Snehana Massage or external 
oleation (centripetal upper 
strokes on the body) 
100 ml Azadirechta indica (neem) 
extract processed in sesame oil 
20 minutes 
Swedana Passive heat therapy to the 
body 
Dashmoola (group of ten herbal 
roots) with steam at <40 degrees 
Celsius) 
15-20 minutes + 3-4 
minutes of relaxation 
after procedure 
Basti kadha Per-rectal drug 
administration should be 
in body for > 15 minutes 
for maximum absorption 
Mixture of 40% Gudmaar (Gymnema 
sylvestre), 20% Daruharidra 
(Berberis aristate) and 40% 
Yashtimadhu (Glycyrrhiza glabra) 
10 minutes 
On day 1 of CDC, the patients have undergone 
HbA1c, weight, BMI, abdominal girth measurements 
as per guidelines.[4] This reading was considered as 
baseline reading. This process was repeated on day 
90 of CDC to calculate the change from baseline 
reading. The BMI for day 1 and day 90 of the patients 
was calculated by checking the weight and the height 
from the medical data sheets of patients and using 
the formula: weight in kilograms/(height in meters)2. 
The dependency on standard medication was 
calculated both on day 1 and day 90 of CDC as the 
percentage of patients out of the total enrolled ones 
who required a conventional allopathic therapeutic 
agent during the study period of 90 days. 
 
 
 
Statistical analysis 
Data were pooled and entered in Microsoft 
Excel spreadsheet. R Version 3.4.1 software was used 
to analyze the data. Categorical data were 
represented in the numeric form and continuous data 
were presented as the Mean ± SD. The Paired t-test 
was used to assess the difference between baseline 
values and 90th day after the treatment. Box plot, 
histograms and scatter plot were used to represent 
the graphs.  
RESULTS 
Study population 
A total of 27 patients’ data was screened for 
inclusion in the study. However, based on the 
availability of data (Day 1 and Day 90) and the 
inclusion criteria, 22 patients were selected, and their 
data were considered for analysis. 
 
Figure 1: Treatment Plan of Comprehensive Diabetes Care Management 
The study comprised of 22 type II diabetic obese patients, among them 10 (45.45%) were men and 12 
(54.55%) were female. The mean age of the study patients was 48 ± 12.13 years. A significant improvement in 
weight, (77.11 ± 12.27 vs. 83.67 ± 11.28; P < 0.001), BMI (31.13 ± 3.91 vs. 33.79 ± 3.80; P < 0.001), HbA1c (6.98 
± 1.73 vs. 8.80 ± 0.93; P = 0.0002) and abdomen girth (96.97 ± 11.93 vs. 104.34 ± 9.74; P < 0.001) were 
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observed in diabetic obese patients after the treatment (90 days) than before treatment (baseline) (Table 2; 
Figure 2). 
Table 2: Comparison of clinical parameters between baseline values and 90th day of the treatment 
Variable Baseline (Day 1) After 90 days Difference  P value 
Weight 83.67 ± 11.28 77.11 ± 12.27 6.56 <0.001 
BMI 33.79 ± 3.80 31.13 ± 3.91 2.66 <0.001 
HbA1c 8.80 ± 0.93 6.98 ± 1.73 1.1 0.0002 
Abdomen Girth (n=19) 104.34 ± 9.74 96.97 ± 11.93 7.37 <0.001 
BMI, Body Mass Index; HbA1c, Glycosylated hemoglobin 
 
Figure 2: Comparison of clinical parameters between baseline values and 90th day (N = 22) 
Most of the type II diabetic obese patients were treated with beta blockers (13.64%), nonsteroidal anti-
inflammatory drugs (13.64%), biguanides (54.55%) and sulfonylureas (36.36%). While, the patients depending 
only on biguanides (36.36%) showed marked decrease after the treatment i.e., 90 days. The patients with the 
absence of medication history (40.91%) were also improved after treatment (Table 3; Figure 3).  
Table 3: Consumption of allopathic medicines on days 1 and 90 
Medicine Baseline After 90 days 
Alpha-glucosidases inhibitors 1 (4.55) 1 (4.55) 
DPP-4 inhibitor 3 (13.64) 1 (4.55) 
Thiazolidinedione 1 (4.55) 1 (4.55) 
Biguanide 12 (54.55) 8 (36.36) 
Sulfonylurea 8 (36.36) 8 (36.36) 
Antiplatelet 1 (4.55) 1 (4.55) 
CCB 1 (4.55) 1 (4.55) 
Beta blocker 3 (13.64) 3 (13.64) 
ARB 2 (9.09) 1 (4.55) 
Statin 1 (4.55) 1 (4.55) 
NSAID 3 (13.64) 3 (13.64) 
No medicine 6 (27.27) 9 (40.91) 
NSAID, Nonsteroidal anti-inflammatory drugs; ARB, Angiotensin II receptor blockers; CCB, Calcium channel 
blockers; DPP-4 inhibitor, Dipeptidyl peptidase-4 
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Figure 3: Consumption of allopathy medicines at days 1 and 90 days (N = 22) 
NSAID, Nonsteroidal anti-inflammatory drugs; ARB, Angiotensin II receptor blockers; CCB, Calcium channel 
blockers; DPP-4 inhibitor,Dipeptidyl peptidase-4 
The levels of HbA1c were significantly correlated with the BMI after 90 days of treatment (r = 0.504; P = 0.016) 
when compared with baseline values (r = 0.39; P = 0.071). (Table 4; Figure 4). 
Table 4: Correlation of BMI and abdominal girth with HbA1c at 1st day and after 90 days of treatment 
Correlation between Baseline After 90 days 
r P value r P value 
HbA1c & BMI 0.39 0.071 0.504 0.016 
BMI, Body Mass Index; HbA1c, Glycosylated haemoglobin 
 
BMI, Body Mass Index; HbA1c, Glycosylated hemoglobin 
Figure 4: Correlation of BMI and abdominal girth with HbA1c at 1st day and after 90 days of treatment 
DISCUSSION 
Although there are numerous treatment 
choices available for treatment of type II DM 
management, it is still one of the commonest culprits 
of morbidity and mortality globally. Thus, it is the 
need of the hour to explore novel therapeutic 
alternatives for the management of type II DM. 
Traditional class of antidiabetic drugs has 
therapeutic benefit in DM of lowering blood sugar 
levels. Similar property has been found in various 
herbal drugs, thus making Ayurveda a potent and 
viable alternative to standard therapy in the 
management of type II DM. Panchakarma is 
administered as add on therapy for DM management, 
by Ayurveda physicians.[23] CDC combines 
Panchakarma with Low carb moderate protein and 
low fat diet. CDC acts by reducing sympathetic stress; 
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reduced sympathetic action lowers hepatic glucose 
production, which can be helpful to reduce blood 
sugar levels. Swedana helps by inducing sweating and 
reduces excess of sodium and water, and this 
comprehensively helps to improve vascular health of 
DM patients to keep them away from probable 
vascular complications.[24] In pursuit of analyzing the 
efficacy of CDC in type II DM, we found that it showed 
significant (very high statistical significance) 
improvement in HbA1c, weight, BMI, abdominal girth 
at the 90th day of the whole procedure. Most 
importantly, we found that CDC noticeably reduced 
patient’s dependency on standard allopathic 
medication at the end of 90 days, may be of therapy. 
The HbA1c levels are more important in 
diabetic patients since it reflects the average blood 
sugar control over the past 1-2months.[25] Importance 
of HbA1c lies in the fact that, it is an independent 
predictor of mortality and morbidity in patients with 
type II DM. This has been corroborated in a 
prospective study done on diabetic patients, that 
cardiovascular complication like stroke was 
significantly lower in patients with an optimal 
reduction in HbA1c. It was found in large study- 
UKPDS study on diabetic patients, that reduction in 
HbA1c by 1% led to reduction of heart failure, heart 
attack, stroke, amputation and overall morbidity and 
mortality in diabetic patients.[25] Hence, significant 
reduction in HbA1c after CDC in our study indicates 
favorable prognosis in DM related morbidity. 
High BMI is considered to be one of the major 
risk factor for development of DM in normal subjects. 
It signifies sedentary lifestyle and obesity.[26] Also, it 
has been found that BMI is positively associated with 
type II diabetes mellitus, hypertension, 
cardiovascular diseases and other chronic 
diseases.[27]  Uncontrolled DM frequently leads to the 
development of complications, hence various 
management plans across the globe have targeted 
sustained blood sugar control in patients with DM, to 
prevent the occurrence of such complications.[4] In 
the present study, CDC significantly reduced HbA1c, 
BMI, abdominal girth, body weight. Thus CDC can 
play significant role in preventing the development of 
complications in patients with DM, thereby reducing 
morbidity and mortality. 
In developing economy like India, the 
dependency of diabetic patients on allopathic 
medicines escalates the cost of healthcare to 
troublesome levels. Plethora of adverse effects of 
these drugs complicates the scenario, furthermore.[28] 
Keeping this in mind, we analyzed changes in 
patient’s dependency on allopathic medication by 
CDC. There was significant reduction in dependency 
on almost all the class of antidiabetic drugs (oral 
hypoglycemic agents), at the end of 90 days, with an 
increase in the number of patients who went off the 
allopathic drugs.  
One limitation of the study was that, it had 
only one arm, thus we were not able to compare CDC 
findings with that of standard therapy alone. The 
findings of the present study can be generalized only 
after a comparison with the findings of other such 
studies with probably prospective design, larger 
sample size, and more follow up period. This will help 
in identifying long term outcomes of CDC in the 
management of type II DM.  
CONCLUSION 
There was significant improvement in HbA1c 
after CDC. Also, there was significant reduction in 
patient’s dependency on allopathic medications. 
Significant reduction in HbA1c, coupled with 
reduction in BMI, body weight, abdominal girth after 
CDC indicates a better prognosis in patients with type 
II DM. Hence, CDC may serve as a potent and viable 
alternative to standard allopathic treatment of type II 
DM.  
ACKNOWLEDGEMENT 
The authors thank the study participants and 
their families, without whom this study would not 
have been accomplished.  
REFERENCES 
1. Wild S, Roglic G, Green A et al. Global Prevalence of 
Diabetes: Estimates for the Year 2000 and 
Projections for 2030.Diabetes Care. 2004; 27 (5): 
1047-1053.  
2. International Diabetes Federation (IDF). IDF 
Diabetes Atlas. 7th ed. 2015. Available from: 
http://www.idf.org/idf-diabetesatlas‑seventh‑ 
edition. [Last accessed on 2016 May 11]. 
3. World Health Organization. Global Health 
Observatory Data Repository. 2014. Available 
from: http://www.apps.who.int. [Last accessed on 
2016 Jul 20]. 
4. Definition and diagnosis of diabetes mellitus and 
intermediate hyperglycemia. Retrived from 
http://www.who.int/diabetes/publications/Defin
ition%20and%20diagnosis%20of%20diabetes_ne
w.pdf [Last accessed on Dec 21st 2017]. 
5. Chaturvedi N. The burden of diabetes and its 
complications: Trends and implications for 
intervention. Diabetes Res Clin Pract. 2007; 76(3): 
S3–S12. 
6. Sanghera D, Blackett P. Type II diabetes genetics: 
beyond GWAS. J Diabetes Metab. 2012; 3(198): 
pii6948. 
7. Zatalia S, Sanusi H. The role of antioxidants in the 
pathophysiology, complications, and management 
Int. J. Ayur. Pharma Research, 2018;6(6):6-12 
     IJAPR | June 2018 | Vol 6 | Issue 6  12 
of diabetes mellitus. Acta Med Indones. 2013; 
45(2): 141–147. 
8. Vigersky R. An overview of management issues in 
adult patients with type II diabetes mellitus. J 
Diabetes Sci Technol. 2011; 5(2): 245–250. 
9. Fong D, Aiello L, Gardner T, et al. Retinopathy in 
diabetes. Diabetes Care.2004; 27(1): S84–87. 
10. Elwing J, Gao F, Davidson N, et al. Type II diabetes 
mellitus: the impact on colorectal adenoma risk in 
women. Am J Gastroenterol. 2006; 101(8): 1866–
1871. 
11. Donadon V, Balbi M, Casarin P, et al. Association 
between hepatocellular carcinoma and type II 
diabetes mellitus in Italy: potential role of insulin. 
World J Gastroenterol. 2008; 14(37): 5695–5700. 
12. Garber A. AACE/ ACE comprehensive diabetes 
management algoritm. Endocrine Practice. 2016; 
21 (4): e1-e10. 
13. Chaudhury A, Duvoor C, Reddy V, et al. Clinical 
Review of Antidiabetic Drugs: Implications for 
Type II Diabetes Mellitus Management. Front 
Endocrinol. 2017; 8(6):1-12. 
14. Egede L, Axon R, Zhao Y, et al. Medications non-
adherence in diabetics. Diabetes Care. 2012 35: 
2533-9. 
15. Elder C, Aickin M, Bauer V et al. Randomized Trial 
of a Whole-System Ayurvedic Protocol for Type II 
Diabetes. Alternative Therapies in Health and 
Medicine. 2006; 12(5): 24-30.  
16. Ila T, ChandolaH, Joshi J. Clinical Efficacy of 
Mehamudgara Vati in Type II Diabetes Mellitus. 
Ayu, 2011;32(1):30-39.  
17. Kumari J, Mehta C, Shukla V et al. A Comparative 
Clinical Study of Nya- grodhadi Ghanavati and 
Virechana Karma in the Management of 
Madhumeha. Ayu, 2010; 31: 300-304.  
18. Choudhary K, Sharma P, Sharma V. Hypertension 
and its management through Panchakarma, J of 
Ayurveda and Hol Med. 2015;3(3):28-31. 
19. Uebaba K, Xu F, Ogawa H, et al. Psychoneuro 
immunologic effects of Ayurvedic oil dripping 
treatment. J Altern Complement Med. 2008;14: 
1189–1198. 
20. Perwitasari D, Urbayatua S. Treatment adherence 
and quality of life in diabetes mellitus patients in 
Indonesia. SAGE Open. 2016: 1-7. 
21. Tiwari A, Rao J. Diabetes Mellitus and Multiple 
Therapeutic Approaches of Phytochemicals: 
Present Status and Future Prospects. Current 
Science. 2002;83 (1):30-38.  
22. Sane R, Aklujkar A, Patil A, Mandole R. Effect of 
heart failure reversal treatment as add-on therapy 
in patients with chronic heart failure: A 
randomized, open-label study. Indian Heart 
Journal. 2017;69(3):299-304. 
23. Barve V, Triapthi S, Patra S, et al. Effect of holistic 
module of yoga and Ayurvedic panchkarma in 
type-2 diabetes mellitus-a pilot study. Open 
Journal of Endocrine and Metabolic Diseases. 
2013; 3:90-8. 
24. Giri S, Patnaik S, Kumar K, et al. Potential of 
Ayurvedic panchakarma in prevention and 
management of lifestyle disorders with special 
reference to Madhumeha, J of Ayurveda and Hol 
Med (JAHM).2015;3(5):82-91  
25. “Clinical importance of Glycosylated hemoglobin 
(HbA1c) in diabetes mellitus patients”. https:// 
www.researchgate.net/publication/26575867_Cli
nical_Importance_Of_Glycosylated_Hemoglobin_H
bA1c_In_Diabetes_Mellitus_Patients.[Last accessed 
on march 11th 2018]. 
26. Shihab H, Meoni L, Chu A, et al. Body Mass Index 
and Risk of Incident Hypertension Over the Life 
Course: The Johns Hopkins Precursors Study. 
Circulation. 2012;126:2983-2989. 
27. Tesfaye F, Nawi N, Minh H, et al. Association 
between body mass index and blood pressure 
across three populations in Africa and Asia. 
Journal of Human Hypertension. 2007; 21: 28–37. 
28. Wu Y, Ding Y, Tanaka Y et al. Risk Factors 
Contributing to Type II Diabetes and Recent 
Advances in the Treatment and Prevention. Int J 
Med Sci. 2014; 11(11): 1185-1200. 
 
 
 
 
 
 
Disclaimer: IJAPR is solely owned by Mahadev Publications - dedicated to publish quality research, while every effort has been taken to 
verify the accuracy of the content published in our Journal. IJAPR cannot accept any responsibility or liability for the articles content 
which are published. The views expressed in articles by our contributing authors are not necessarily those of IJAPR editor or editorial 
board members.  
Cite this article as:  
Sane Rohit M, Sabir Imran A, Naik Minal S, Shingan Tejaswini, Mandole Rahul S. 
Comprehensive Diabetes Care (CDC) Management Program in Type II Diabetic 
Obese Patients. International Journal of Ayurveda and Pharma Research. 
2018;6(6):6-12. 
Source of support: Nil, Conflict of interest: None Declared 
 
*Address for correspondence 
Dr Mandole Rahul S 
Department of Research and 
Development, Madhavbaug 
Cardiac Care Clinics and 
Hospitals. Mumbai, India,  
Email: cromilagro@gmail.com 
Phone: 7400407193 
